EUCTR2009-011611-21-BE进行中（未招募）1 期
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Eli Lilly and Company Ltd.0 个研究点目标入组 65 人开始时间: 2009年8月21日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 65
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[1] Histologically confirmed diagnosis of squamous cell carcinoma of head and neck (SCCHN)
- •o Recurrent or metastatic SCCHN, not amenable to local therapy
- •o At least 6 months since completion of systemic therapy (chemotherapy or biological anticancer therapy)
- •o No more than 1 prior systemic therapy, given as part of multimodal treatment for locally advanced disease; induction chemotherapy and subsequent concurrent chemoradiation are considered as 1 regimen
- •o No prior systemic therapy for metastatic disease
- •[2] Prior therapies:
- •o Radiation therapy must be completed at least 4 weeks before study enrollment (first dose of study therapy). For palliative therapy, prior radiation therapy allowed to <25% of the bone marrow (Cristy and Eckerman 1987), and prior radiation to the whole pelvis is not allowed. Patients must have recovered from the acute toxic effects of the treatment prior to study enrollment.
- •o Surgery (excluding prior diagnostic biopsy) must be completed at least 4 weeks before study enrollment. Patients must have fully recovered from any acute effects of surgery prior to study enrollment.
- •[3] An estimated life expectancy of at least 12 weeks.
- •[4] Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Oken et al. 1982).
- •[5] Biological tissue available for biomarker analysis on tumor tissue.
- •[6] Disease status may be measurable or nonmeasurable as defined by Response Evaluation Criteria in Solid Tumors (RECIST; Therasse et al. 2000; Protocol Attachment S123.4). Positron emission tomography (PET) scans and ultrasounds may not be used for lesion measurements.
- •[7] Patient compliance and geographic proximity that allow for adequate follow-up.
- •[8] Adequate organ function as defined by the following:
- •o Bone marrow reserve: absolute neutrophil (segmented and bands) count (ANC) = 1.5 billion per litre, platelets = 100 billion per litre, and hemoglobin = 9 g/dL.
- •o Hepatic: bilirubin = 1.5 × the upper limit of normal (ULN); alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) = 3.0 × ULN (ALP, AST, and ALT = 5.0 × ULN is acceptable if the liver has tumor involvement).
- •o Renal: calculated creatinine clearance (CrCl) = 60 mL/min. These tests must be performed within 7 days prior to Day 1 of Cycle 1.
- •[9] Signed informed consent from patient.
- •[10] Patients at least 18 years of age.
- •[11] For women: Must be surgically sterile, postmenopausal, or compliant with a medically approved contraceptive regimen (for example, intrauterine device [IUD], birth control pills, or barrier device) during and for 6 months after the treatment period; must have a negative serum or urine pregnancy test within 7 days before study enrollment, and must not be breast-feeding. For men: Must be surgically sterile or compliant with a contraceptive regimen during and for 6 months after the treatment period.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •[12] Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
- •[13] Previously received treatment with monoclonal antibody therapy, or other signal transduction inhibitors of EGFR-targeting therapy.
- •[14] Are receiving concurrent chronic systemic immune therapy, or chemotherapy for a disease other than cancer.
- •[15] Concurrent administration of any other antitumor therapy.
- •[16] Known prior allergic/hypersensitivity reaction to any of the components of the study treatment.
- •[17] Serious concomitant systemic disorder (for example, active infection) or psychiatric disorder that, in the opinion of the investigator, would compromise the patient’s ability to complete the study.
- •[18] Have serious cardiac disease, such as symptomatic angina [NYHA grade III and IV], unstable angina, or the history of myocardial infarction in the previous 12 months.
- •[19] Second primary malignancy that is clinically detectable at the time of consideration for study enrollment.
- •[20] Have had another primary malignancy other than HNC, unless that prior malignancy was treated at least 2 years previously with no evidence of recurrence. Exception: Patients with a history of in situ carcinoma of the cervix, nonmelanoma skin cancer, or low-grade (Gleason score = 6) localized prostate cancer will be eligible even if diagnosed and treated less than 2 years previously.
- •[21] Nasopharyngeal, paranasal sinus, lip, or salivary gland cancer.
- •[22] Presence of clinically significant (by physical exam) third-space fluid collections; for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry.
- •[23] Have peripheral neuropathy of Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or higher.
- •[24] Have central nervous system (CNS) metastases (unless the patient has completed successful local therapy for CNS metastases and has been off corticosteroids for at least 4 weeks before starting study therapy). Brain imaging is required in symptomatic patients to rule out brain metastases, but is not required in asymptomatic patients.
- •[25] Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than an aspirin dose = 1.3 grams per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam).
- •[26] Unable or unwilling to take folic acid, vitamin B12, or prophylactic corticosteroids.
- •[27] Recent (within 30 days before enrollment) or concurrent yellow fever vaccination.
- •[28] Pregnant or breast-feeding.
研究者
相似试验
进行中（未招募）
不适用
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckEstudio en fase II de pemetrexed en combinación con cisplatino y cetuximab en el carcinoma de células escamosas de cabeza y cuello recurrente o metastásicoRecurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCarcinoma de células escamosas de cabeza y cuello recurrente o metastásicoMedDRA version: 12.0Level: LLTClassification code 10063569Term: Metastatic squamous cell carcinomaEUCTR2009-011611-21-ESEli Lilly and Company Ltd.65
进行中（未招募）
不适用
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckEUCTR2009-011611-21-DEEli Lilly and Company Ltd.65
进行中（未招募）
1 期
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckEUCTR2009-011611-21-GBEli Lilly and Company Ltd.65
进行中（未招募）
不适用
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck - NDRecurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckMedDRA version: 9.1Level: LLTClassification code 10063569EUCTR2009-011611-21-ITEli Lilly and Company Ltd.
招募中
2 期
Phase II Study of Pemetrexed in Combination with Carboplatin Followed by Pemetrexed Maintenance Therapy for Elderly Advanced Non-squamous and Non-small Cell Lung Cancer.on-squamous non-small-cell lung cancerJPRN-UMIN000006139Tochigi Thoracic Oncology Research Organization50